Connor Clark & Lunn Investment Management Ltd. lessened its stake in shares of Lantheus Holdings Inc (NASDAQ:LNTH) by 2.9% during the third quarter, HoldingsChannel.com reports. The fund owned 275,011 shares of the medical equipment provider’s stock after selling 8,300 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in Lantheus were worth $4,111,000 as of its most recent SEC filing.
Several other institutional investors also recently added to or reduced their stakes in LNTH. BlackRock Inc. lifted its position in shares of Lantheus by 20.1% during the 3rd quarter. BlackRock Inc. now owns 5,579,963 shares of the medical equipment provider’s stock valued at $83,419,000 after acquiring an additional 933,791 shares during the period. LSV Asset Management lifted its position in shares of Lantheus by 135.6% during the 3rd quarter. LSV Asset Management now owns 865,921 shares of the medical equipment provider’s stock valued at $12,945,000 after acquiring an additional 498,435 shares during the period. Russell Investments Group Ltd. lifted its position in shares of Lantheus by 208.2% during the 2nd quarter. Russell Investments Group Ltd. now owns 618,775 shares of the medical equipment provider’s stock valued at $9,004,000 after acquiring an additional 417,978 shares during the period. Bank of America Corp DE raised its holdings in Lantheus by 2,808.1% during the second quarter. Bank of America Corp DE now owns 429,413 shares of the medical equipment provider’s stock worth $6,248,000 after buying an additional 414,647 shares during the last quarter. Finally, Boston Partners raised its holdings in Lantheus by 198.1% during the second quarter. Boston Partners now owns 356,790 shares of the medical equipment provider’s stock worth $5,191,000 after buying an additional 237,090 shares during the last quarter. Institutional investors own 92.39% of the company’s stock.
Several research firms have weighed in on LNTH. ValuEngine upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a report on Saturday. BidaskClub upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a report on Thursday, November 22nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $22.67.
Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Tuesday, October 30th. The medical equipment provider reported $0.24 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.18 by $0.06. Lantheus had a net margin of 36.75% and a return on equity of 83.95%. The firm had revenue of $88.90 million for the quarter, compared to the consensus estimate of $83.53 million. During the same quarter in the prior year, the company posted $0.24 earnings per share. The business’s revenue was up 11.1% on a year-over-year basis. On average, equities research analysts anticipate that Lantheus Holdings Inc will post 0.86 earnings per share for the current year.
In other Lantheus news, insider Cesare Orlandi sold 7,055 shares of the company’s stock in a transaction on Friday, November 30th. The shares were sold at an average price of $18.01, for a total transaction of $127,060.55. Following the transaction, the insider now owns 86,064 shares in the company, valued at $1,550,012.64. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 1.20% of the company’s stock.
WARNING: “Connor Clark & Lunn Investment Management Ltd. Reduces Position in Lantheus Holdings Inc (LNTH)” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.com-unik.info/2018/12/04/connor-clark-lunn-investment-management-ltd-reduces-position-in-lantheus-holdings-inc-lnth.html.
Lantheus Company Profile
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow.
Featured Article: How to Track your Portfolio in Google Finance
Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings Inc (NASDAQ:LNTH).
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.